Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Clinical trial NCT03971734 · TERMINATED
Trial details
- NCT number
- NCT03971734
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-06
- Primary completion
- 2022-04-30
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.